Status:
UNKNOWN
Lung Bacteriobiota and Influenza Mortality
Lead Sponsor:
University of Bordeaux
Conditions:
Influenza
Critical Illness
Eligibility:
All Genders
18+ years
Brief Summary
Influenza is a potentially lethal disease still responsible for thousands excess deaths both in Europe and the United States. Despite the use of neuraminidase inhibitors, its treatment is mostly based...
Detailed Description
Influenza is a viral disease which is still responsible for thousands of excess deaths par year both in Europe and in the US. Despite the use of neuraminidase inhibitors, its treatment is mostly based...
Eligibility Criteria
Inclusion
- Patient above 18 year-old admitted to intensive care unit
- Influenza diagnosis by PCR or rapid diagnostic test
Exclusion
- Guardianship or curatorship
- Prisoners
- No health insurance
- No legal representative
Key Trial Info
Start Date :
December 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2020
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT04131296
Start Date
December 1 2019
End Date
April 30 2020
Last Update
November 1 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical intensive care unit, Pellegrin hospital
Bordeaux, Nouvelle-Aquitaine, France, 33000
2
Intensive care unit, CH Robert Boulin
Libourne, France, 33500
3
Intensive care unit, CH Francois Mitterrand
Pau, France, 64000